Suppr超能文献

HMG-CoA还原酶抑制剂的直接血管效应。

Direct vascular effects of HMG-CoA reductase inhibitors.

作者信息

Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, Fumagalli R, Paoletti R, Corsini A

机构信息

Institute of Pharmacological Sciences, University of Milan, Milano, Italy.

出版信息

Atherosclerosis. 1998 Apr;137 Suppl:S101-9. doi: 10.1016/s0021-9150(97)00319-5.

Abstract

Several studies have demonstrated that any beneficial effect of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) on coronary events are linked to their hypocholesterolemic properties. However, since mevalonic acid (MVA), the product of the enzyme reaction, is the precursor of numerous metabolites, inhibition of HMG-CoA reductase has the potential to result in pleiotropic effects. MVA and other intermediates of cholesterol synthesis (isoprenoids) are necessary for cell proliferation and other important cell functions, hence effects other than cholesterol reduction may help to explain the antiatherosclerotic properties of statins. Recently, we provided in vitro evidence that fluvastatin, simvastatin, lovastatin, cerivastatin, but not pravastatin, dose-dependently decrease smooth muscle cells (SMC) migration and proliferation, independently of their ability to reduce plasma cholesterol. Moreover, statins are able to reduce the in vitro cholesterol accumulation in macrophages, by blocking cholesterol esterification and endocytosis of modified lipoproteins. This in vitro inhibition was completely prevented by the addition of mevalonate and partially by all-trans farnesol and all-trans geranylgeraniol, confirming the specific role of isoprenoid metabolites--probably through a prenylated protein(s)--in regulating these cellular events. The inhibitory effect of lipophilic statins on SMC proliferation has been recently shown in different models of proliferating cells such as cultured arterial myocytes and rapidly proliferating carotid and femoral intimal lesions in rabbits. Finally, ex vivo studies recently showed that sera from fluvastatin-treated patients interfere with smooth muscle cell proliferation. These results suggest that HMG-CoA reductase inhibitors exert a direct antiatherosclerotic effect in the arterial wall, beyond their effects on plasma lipids, that could translate into a more significant prevention of cardiovascular disease.

摘要

多项研究表明,3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂(他汀类药物)对冠状动脉事件的任何有益作用都与其降胆固醇特性有关。然而,由于酶反应产物甲羟戊酸(MVA)是众多代谢产物的前体,抑制HMG-CoA还原酶有可能产生多效性作用。MVA和胆固醇合成的其他中间体(类异戊二烯)是细胞增殖和其他重要细胞功能所必需的,因此除降低胆固醇之外的作用可能有助于解释他汀类药物的抗动脉粥样硬化特性。最近,我们提供了体外证据表明,氟伐他汀、辛伐他汀、洛伐他汀、西立伐他汀,但普伐他汀除外,剂量依赖性地降低平滑肌细胞(SMC)迁移和增殖,这与其降低血浆胆固醇的能力无关。此外,他汀类药物能够通过阻断胆固醇酯化和修饰脂蛋白的内吞作用来减少巨噬细胞体外胆固醇蓄积。添加甲羟戊酸可完全阻止这种体外抑制作用,而全反式法尼醇和全反式香叶基香叶醇可部分阻止这种抑制作用,这证实了类异戊二烯代谢产物——可能通过一种异戊二烯化蛋白——在调节这些细胞事件中的特定作用。最近在不同的增殖细胞模型中,如培养的动脉肌细胞以及兔快速增殖的颈动脉和股动脉内膜病变模型中,均显示了亲脂性他汀类药物对SMC增殖的抑制作用。最后,体外研究最近表明,氟伐他汀治疗患者的血清会干扰平滑肌细胞增殖。这些结果表明,HMG-CoA还原酶抑制剂在动脉壁发挥直接的抗动脉粥样硬化作用,这超出了它们对血脂的作用,可能会转化为对心血管疾病更显著的预防作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验